LoginSignup
Novocure logo

Novocure Stock

StockStock
ISIN: JE00BYSS4X48
Ticker: NVCR
JE00BYSS4X48
NVCR

Price

Frequently asked questions

What is Novocure's market capitalization?

The market capitalization of Novocure is $1.97B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.

What is the Earnings Per Share (EPS) for Novocure?

Novocure's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.394. EPS indicates the company's profitability on a per-share basis.

What are the analyst ratings and target price for Novocure's stock?

Currently, 7 analysts cover Novocure's stock, with a consensus target price of $27.42. Analyst ratings provide insights into the stock's expected performance.

What is Novocure's revenue over the trailing twelve months?

Over the trailing twelve months, Novocure reported a revenue of $577.74M.

What is the EBITDA for Novocure?

Novocure's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$146.04M. EBITDA measures the company's overall financial performance.

What is the free cash flow of Novocure?

Novocure has a free cash flow of -$78.21M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.

What is the 5-year beta of Novocure's stock?

The 5-year beta for Novocure is 0.71. A beta value indicates the stock's volatility relative to the market; a beta greater than 1 means higher volatility.

How many employees does Novocure have, and what sector and industry does it belong to?

Novocure employs approximately 1,453 people. It operates in the Health Care sector, specifically within the Biotechnology & Drugs industry.

What is the free float of Novocure's shares?

The free float of Novocure is 98.19M. Free float refers to the number of shares available for public trading, excluding restricted shares.

Financials

Market Cap

 $1.97B

5Y beta

 0.71

EPS (TTM)

 -$1.394

Free Float

 98.19M

Revenue (TTM)

 $577.74M

EBITDA (TTM)

 -$146.04M

Free Cashflow (TTM)

 -$78.21M

Pricing

1D span
$17.61$18.61
52W span
$11.29$24.74

Analyst Ratings

The price target is $27.42 and the stock is covered by 7 analysts.

Buy

3

Hold

4

Sell

0

Information

NovoCure Limited is a global oncology company. The Company is engaged in the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune and Optune Lua for the treatment of solid tumor cancers. Its commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma, malignant pleural mesothelioma and pleural mesothelioma. It is conducting pivotal studies evaluating the use of TTFields in the treatment of ovarian cancer, brain metastases from non-small cell lung cancer (NSCLC) (brain metastases) and pancreatic cancer. Its key priorities are to drive commercial adoption of Optune, its commercial TTFields device. It also has a license to market Optune in China, Hong Kong, Macau and Taiwan. It has ongoing or completed clinical trials investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

1,453

Biotechnology & Drugs

Health Care

Identifier

ISIN

JE00BYSS4X48

Primary Ticker

NVCR

Knockouts

Join the conversation
Sign upLogin